Previous 10 | Next 10 |
Investment thesis: As mentioned in our previous articles, Eonia Research focuses heavily on analyzing the underlying science of biotechs. After a prolonged search, we have found an intriguing biotech operating in the chimeric antigen receptor T-cell (CAR-T) space, Autolus therapeutics ( AUTL...
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS). Dear Shareholders, In the context of the COVID-19 epidemic and in accordance with Ordinance No. 2020-321 of March 25, 2020, the annual general meeting will take place on June 29, 2020 at 9 AM...
Image source: The Motley Fool. Cellectis SA (NASDAQ: CLLS) Q1 2020 Earnings Call May 8, 2020 , 5:30 p.m. ET Operator Continue reading
Cellectis S.A. (CLLS) Q1 2020 Earnings Conference Call May 7, 2020 7:30 AM ET Company Participants Simon Harnest – Vice President-Corporate Strategy and Finance André Choulika – Chairman and Chief Executive Officer Carrie Brownstein – Chief Medical Offic...
Cellectis (NASDAQ: CLLS ): Q1 Non-GAAP EPS of $0.57; GAAP EPS of $0.47 beats by $1.12 . Revenue of $51.9M (+1426.5% Y/Y) beats by $36.93M . Press Release More news on: Cellectis S.A., Earnings news and commentary, Healthcare stocks news,
Proprietary allogeneic CAR T-cell programs on track in Phase 1 dose escalation trials; AMELI-01 in r/r AML patients, BALLI-01 in r/r B-ALL patients and MELANI-01 in r/r MM patients Appointed Chief Medical Officer, Carrie Brownstein, M.D., who joins from Celgene Construction pr...
NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report the first quarter 2020 on We...
NEW YORK, April 13, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced the appointment of Carrie Brownstein, M.D....
Introduction Since my last article on Allogene Therapeutics ( ALLO ) about 5 months ago, its share price has fallen by around 30%, largely in part due to the stock market crash driven by the COVID-19 global pandemic . Despite the progress in clinical development, strong management tea...
Introduction Sangamo Therapeutics ( SGMO ) is a clinical-stage biotech company focusing on the research and development of genomic medicine across 4 distinct technology platforms: gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. Sangamo is best-known for...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...